



Ignacio Pérez Catalán¹
Adriana Gascón Buj²
Sergio García Muñoz³
Iris Gómez Alfaro⁴
Celia Roig Martí¹
Miguel Torres García⁵
Roberto Reig Valero⁶
Raúl Ferrando Piqueres³
Lidón Mateu Campos⁶
José Manuel Ramos Rincón⁷
Jorge Usó Blasco¹

Nirmatrelvir/ritonavir as a possible treatment for Long-COVID

¹Internal Medicine, General University Hospital of Castellón, Castellón de la Plana, Spain

²Hematology, General University Hospital of Castellón, Castellón de la Plana, Spain

³Hospital Pharmacy, General University Hospital of Castellón, Castellón de la Plana, Spain

⁴Clinical Microbiology, General University Hospital of Castellón, Castellón de la Plana, Spain

⁵Pneumology, General University Hospital of Castellón, Castellón de la Plana, Spain

⁶Intensive Care Medicine, General University Hospital of Castellón, Castellón de la Plana, Spain

⁷Internal Medicine, General University Hospital of Alicante, Alicante, Spain

Article history

Received: 21 March 2023; Revision Requested: 21 April 2023; Revision Received: 24 April 2023; Accepted: 8 May 2023;

Published: 27 June 2023

Sir,

It is estimated that about 10% of patients who have been infected with SARS-CoV-2 worldwide suffer from Long-Covid, about 65 million people [1]. Although we are beginning to know its pathophysiology, there is still no evidence on its treatment. We present the case of a patient with persistent prolonged symptoms who had an optimal response to nirmatrelvir/ritonavir 2 years after acute infection.

A 38-year-old woman with a history of psoriasis (untreated and well controlled) who, after receiving the first dose of Pfizer-BioNTech® vaccine on January 13, 2021, presented with headache, fever of 38°C and myalgias. Given the persistence of symptoms after 48 hours, RT-PCR against SARS-CoV-2 (ARGENE® SARS-COV-2 R-GENE®) was performed and was positive. No antiviral treatment was administered. Anosmia, ageusia and dry cough were added to the referred symptomatology. On February 8, serology was performed, detecting IgG against protein S of SARS-CoV-2 by chemiluminescence technique (CLIA) in automated equipment (Liaison® SARS-CoV-2 S1/S2 IgG). Given the persistence of symptoms, including hyperthermia, corticotherapy was started at medium doses for 3 weeks. She presented better thermal and other symptom control but persisted with afternoon low-grade fever. He was referred to the Post-Covid-19 consultation of the Infectious Diseases Unit.

In a first contact, physical examination was normal and complementary tests were requested in which only elevated values of erythrocyte sedimentation rate [ESR: 20 mm/h (0-10)] and D-dimer [900 ng/mL (0-500)], with autoimmunity, hemogram, proteinogram, acute phase reactants, immunoglobulins, lymphocyte populations, liver enzymes, ions, hormone and vitamin studies were unremarkable. Serology was negative and RT-PCR against SARS-CoV-2 was repeated several times and

was always negative. A second course of corticosteroids was started, with no response, persisting with poorly tolerated afternoon low-grade fever with headache, asthenia, myalgia and atypical chest pain. A complete computed axial tomography (CAT) scan was performed, showing adenopathies of non-significant size at the cervical, retroperitoneal and mesenteric levels. A positron emission tomography (PET) scan was requested, which only reported diffuse inflammatory gastric hypermetabolism, so gastroscopy was performed with biopsies that ruled out pathology including infection by *Tropheryma whipplei*. The initial analytical study was repeated 10 months after the onset of the clinical picture, adding tumor markers and extraction of blood cultures, and again the results were irrelevant.

One year after the onset of symptoms and due to the persistence of a poorly tolerated daily afternoon fever, treatment with colchicine was tried as an immunomodulator and a genetic study of autoinflammatory syndrome was requested, which was negative. After starting colchicine, the patient was afebrile and her general symptoms improved. The treatment was maintained for 5 months with good control and after its withdrawal she again presented low-grade fever and worsening of the previous symptoms. Colchicine was reintroduced at the same dose and again she was asymptomatic.

A few weeks later, despite continuing with colchicine, the low-grade fever reappeared and she presented a significant clinical deterioration that did not improve despite increasing the dose. Finally, two years after the onset of symptoms and after the approval by a multidisciplinary committee after the good response described by Peluso et al. of 4 patients with Long-Covid [2], we withdrew colchicine and started antiviral treatment against SARS-CoV-2 (off-label) with nirmatrelvir/ritonavir for 5 days with immediate resolution of symptoms. After 6 weeks of treatment, she has not presented low-grade fever or the symptoms previously mentioned.

Long-Covid has been more frequently associated with ages between 36-50 years, female sex and independently of the

Correspondence:
Celia Roig Martí

Internal Medicine, General University Hospital of Castellón, Castellón de la Plana, Spain
E-mail: celia.roig.marti@gmail.com

severity of the acute infection [3]. Multiple hypotheses have been proposed, including the persistence of viral activity from certain reservoirs [4,5]. We suggest that, in the present case, viral persistence would have triggered a persistent inflammatory response, causing the symptomatology. Colchicine would have modulated the inflammatory response, thus explaining the good symptomatic control with its administration and the worsening with withdrawal.

After a literature review, we found only 4 case reports describing a clear improvement after the use of nirmatrelvir/ritonavir in patients with persistent symptoms after acute infection [2]. However, in most of them it was administered a few weeks later and after re-infection and none of them had such a prolonged and disabling evolution as in the referred patient. In addition, a recent preprint shows a decrease in the incidence of Long-Covid with the use of nirmatrelvir/ritonavir in the acute phase, supporting the practice [6].

In conclusion, the persistence of viral activity after acute infection could be a cause of Long-Covid and in this sense, the use of nirmatrelvir/ritonavir is a treatment option. However, the evidence is scarce and there are probably other influencing factors such as immune dysregulation, alteration of the microbiota or vascular microthrombosis and endothelial dysfunction [5].

FUNDING

None to declare

CONFLICT OF INTEREST

Authors declare no conflict of interest

REFERENCES

1. Ballering AV, van Zon SKR, Olde Hartman TC, et al. Lifelines Corona Research Initiative. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. *Lancet*. 2022 Aug 6;400(10350):452-461. doi: 10.1016/S0140-6736(22)01214-4.
2. Peluso MJ, Anglin K, Durstenfeld MS, et al. Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies. *Pathog Immun*. 2022 Jun 24;7(1):95-103. doi: 10.20411/pai.v7i1.518.
3. FAIR Health. *Patients Diagnosed with Post-COVID Conditions: An Analysis of Private Healthcare Claims Using the Official ICD-10 Diagnostic Code* (FAIR Health, 2022). Available from: <https://www.fairhealth.org/article/fair-health-releases-study-on-post-covid-conditions>
4. Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, Walt DR. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. *Clin Infect Dis*. 2022 Sep 2;ciac722. doi: 10.1093/cid/ciac722.
5. Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. *Front Microbiol*. 2021 Jun 23;12:698169. doi: 10.3389/fmicb.2021.698169.
6. Xie Y, Choi T, Al-Aly Z. Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition. *JAMA Intern Med*. 2023 Mar 23:e230743. doi: 10.1001/jamainternmed.2023.0743.